Regeneron Pharmaceuticals (LTS:0R2M) Common Stock : $0 Mil (As of Jun. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Regeneron Pharmaceuticals Common Stock?

Regeneron Pharmaceuticals's quarterly common stock stayed the same from Dec. 2023 ($0 Mil) to Mar. 2024 ($0 Mil) and stayed the same from Mar. 2024 ($0 Mil) to Jun. 2024 ($0 Mil).

Regeneron Pharmaceuticals's annual common stock stayed the same from Dec. 2021 ($0 Mil) to Dec. 2022 ($0 Mil) and stayed the same from Dec. 2022 ($0 Mil) to Dec. 2023 ($0 Mil).

Regeneron Pharmaceuticals Common Stock Historical Data

The historical data trend for Regeneron Pharmaceuticals's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Common Stock Chart

Regeneron Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

0.10

Regeneron Pharmaceuticals Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Common Stock	Get a 7-Day Free Trial															0.10	0.10	0.10	0.10	0.10

Regeneron Pharmaceuticals Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Regeneron Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (LTS:0R2M) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

REGN:USA REGN:Mexico 1REGN:Italy RGO:Germany RGO:Germany REGN34:Brazil REGN:Austria

Address

777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707

Website

https://www.regeneron.com

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

Regeneron Pharmaceuticals Headlines

No Headlines